12 月龄时，1 剂、2 剂或 3 剂婴幼儿期 7 价肺炎球菌结合疫苗后，23 价肺炎球菌多糖疫苗的安全性和免疫原性。
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
机构信息
Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia.
出版信息
Vaccine. 2010 Apr 19;28(18):3086-94. doi: 10.1016/j.vaccine.2010.02.065. Epub 2010 Mar 1.
Abstract
Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.
摘要
6 周龄斐济婴儿按种族分层，随机分为接受 0、1、2 或 3 剂 PCV-7 加或不加 12 个月时的 23 价肺炎球菌多糖疫苗（PPV-23）组。所有 7 种 PCV-7 血清型均引起强烈的增强效应，4/7 种血清型在单剂 PCV-7 组的反应最高。所有非 PCV-7 血清型的 GMC 均有 4 倍升高。到 17 个月时，PPV-23 组所有血清型的 GMC 仍显著较高（p<0.001）。PPV-23 耐受性良好，引起所有血清型的良好反应，在单剂 PCV-7 组最大。
相似文献
1
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.12 月龄时，1 剂、2 剂或 3 剂婴幼儿期 7 价肺炎球菌结合疫苗后，23 价肺炎球菌多糖疫苗的安全性和免疫原性。
Vaccine. 2010 Apr 19;28(18):3086-94. doi: 10.1016/j.vaccine.2010.02.065. Epub 2010 Mar 1.
2
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.接种一剂 7 价肺炎球菌结合疫苗后可获得血清型特异性亲合力，并在 12 个月时通过 23 价肺炎球菌多糖疫苗加强剂增强。
Vaccine. 2011 Jun 15;29(27):4499-506. doi: 10.1016/j.vaccine.2011.04.038. Epub 2011 May 1.
3
The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.在婴儿早期接种13价肺炎球菌结合疫苗进行初次免疫的幼儿中，接种10价或13价肺炎球菌结合疫苗加强针后的抗体反应。
Pediatr Infect Dis J. 2016 Jul;35(7):787-93. doi: 10.1097/INF.0000000000001180.
4
Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.23价肺炎球菌多糖疫苗作为3剂7价肺炎球菌结合疫苗初免的12至18月龄儿童加强剂量的免疫原性和安全性
Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.
5
Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.12 月龄时接受 7 价肺炎球菌结合疫苗婴幼儿基础免疫系列接种减少剂量和 23 价肺炎球菌多糖疫苗后的调理吞噬活性。
Vaccine. 2011 Jan 10;29(3):535-44. doi: 10.1016/j.vaccine.2010.10.046. Epub 2010 Oct 31.
6
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.一种七价肺炎球菌结合疫苗在1型人类免疫缺陷病毒感染婴儿中的安全性和免疫原性。
Pediatrics. 2003 Jul;112(1 Pt 1):66-73. doi: 10.1542/peds.112.1.66.
7
Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.12 月龄时接种肺炎球菌多糖疫苗后再挑战剂量时反应低下：一项随机对照试验。
Vaccine. 2010 Apr 26;28(19):3341-9. doi: 10.1016/j.vaccine.2010.02.087. Epub 2010 Mar 4.
8
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.南非儿童中一剂与两剂基础免疫序贯加强一剂 10 价或 13 价肺炎球菌结合疫苗的免疫原性比较：一项开放标签、随机、非劣效性试验。
Lancet Infect Dis. 2020 Dec;20(12):1426-1436. doi: 10.1016/S1473-3099(20)30289-9. Epub 2020 Aug 25.
9
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.14 价肺炎球菌多糖结合疫苗（PNEUBEVAX 14™）在 6-8 周龄健康印度婴儿中的免疫原性和安全性：一项单盲、随机、阳性对照、III 期研究。
Vaccine. 2024 May 10;42(13):3157-3165. doi: 10.1016/j.vaccine.2024.03.056. Epub 2024 Apr 17.
10
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.与7价肺炎球菌结合疫苗相比，13价肺炎球菌结合疫苗在健康婴幼儿中与常规疫苗按三剂程序接种时的安全性和免疫原性。
Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.
引用本文的文献
1
Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan.婴幼儿肺炎球菌结合疫苗接种程序——获取、免疫原性，以及肺炎球菌结合疫苗和黄热病疫苗联合使用的研究：统计分析计划。
Trials. 2024 Mar 26;25(1):216. doi: 10.1186/s13063-024-08036-6.
2
Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial.越南胡志明市简化的 0+1 及 1+1 型肺炎球菌疫苗接种计划：一项随机对照试验方案。
BMJ Open. 2021 Nov 29;11(11):e056505. doi: 10.1136/bmjopen-2021-056505.
3
Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific.澳大利亚在亚太地区肺炎球菌和人乳头瘤病毒疫苗评估中的作用。
Vaccines (Basel). 2021 Aug 18;9(8):921. doi: 10.3390/vaccines9080921.
4
Vaccination for the control of childhood bacterial pneumonia - type b and pneumococcal vaccines.用于控制儿童细菌性肺炎的疫苗——b型疫苗和肺炎球菌疫苗。
Pneumonia (Nathan). 2016 Jul 2;2:2-15. doi: 10.15172/pneu.2013.2/229. eCollection 2013.
5
The association between pneumococcal vaccination, ethnicity, and the nasopharyngeal microbiota of children in Fiji.斐济儿童中肺炎球菌疫苗接种、种族与鼻咽微生物群的关联。
Microbiome. 2019 Jul 16;7(1):106. doi: 10.1186/s40168-019-0716-4.
6
Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial.纳入肺炎球菌疫苗接种的不同婴儿疫苗接种计划评估（越南肺炎球菌项目）：一项随机对照试验方案
BMJ Open. 2018 Jun 8;8(6):e019795. doi: 10.1136/bmjopen-2017-019795.
7
No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.对于先前已接种肺炎球菌多糖疫苗的儿童，接种肺炎球菌结合疫苗后无长期低反应性的证据。
J Allergy Clin Immunol. 2016 Jun;137(6):1772-1779.e11. doi: 10.1016/j.jaci.2015.12.1303. Epub 2016 Jan 26.
8
Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.23价肺炎球菌多糖疫苗作为3剂7价肺炎球菌结合疫苗初免的12至18月龄儿童加强剂量的免疫原性和安全性
Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.
9
Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.用C群脑膜炎奈瑟菌结合疫苗对婴儿进行免疫接种后免疫记忆诱导的评估——一项随机对照试验中的探索性分析
PLoS One. 2014 Jul 14;9(7):e101672. doi: 10.1371/journal.pone.0101672. eCollection 2014.
10
Maternal Supplementation with LGG Reduces Vaccine-Specific Immune Responses in Infants at High-Risk of Developing Allergic Disease.母亲补充 LGG 可降低高过敏风险婴儿对疫苗的特异性免疫应答。
Front Immunol. 2013 Nov 26;4:381. doi: 10.3389/fimmu.2013.00381. eCollection 2013.
本文引用的文献
1
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.5岁以下儿童肺炎链球菌所致疾病负担：全球估计数
Lancet. 2009 Sep 12;374(9693):893-902. doi: 10.1016/S0140-6736(09)61204-6.
2
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.一剂、两剂或三剂7价肺炎球菌结合疫苗后的免疫原性。
Vaccine. 2009 Sep 18;27(41):5685-91. doi: 10.1016/j.vaccine.2009.06.098. Epub 2009 Jul 17.
3
Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.学龄前哮喘患儿序贯肺炎球菌免疫接种的安全性和免疫原性
Vaccine. 2009 Aug 20;27(38):5259-64. doi: 10.1016/j.vaccine.2009.06.054. Epub 2009 Jul 2.
4
Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.7价肺炎球菌结合疫苗对未接种疫苗的家庭成员肺炎球菌定植的间接影响。
Clin Infect Dis. 2008 Oct 15;47(8):989-96. doi: 10.1086/591966.
5
Reconsideration of the use of meningococcal polysaccharide vaccine.对脑膜炎球菌多糖疫苗使用的重新考虑。
Pediatr Infect Dis J. 2007 Aug;26(8):716-22. doi: 10.1097/INF.0b013e3180cc2c25.
6
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?肺炎球菌结合疫苗和多糖疫苗的联合接种程序：低反应性是一个问题吗？
Lancet Infect Dis. 2007 Sep;7(9):597-606. doi: 10.1016/S1473-3099(07)70210-4.
7
Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.在马萨诸塞州对婴儿普遍接种肺炎球菌结合疫苗后，19A作为毒性强且耐多药的肺炎球菌出现。
Pediatr Infect Dis J. 2007 Jun;26(6):468-72. doi: 10.1097/INF.0b013e31803df9ca.
8
Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae.在肺炎链球菌6血清群中发现一种新的荚膜血清型（6C）。
J Clin Microbiol. 2007 Apr;45(4):1225-33. doi: 10.1128/JCM.02199-06. Epub 2007 Jan 31.
9
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.两种七价肺炎球菌结合疫苗在芬兰中耳炎疫苗试验中引发的功能性抗体。
Infect Immun. 2007 Apr;75(4):1794-800. doi: 10.1128/IAI.01673-06. Epub 2007 Jan 29.
10
Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease.结合疫苗对成人肺炎链球菌携带的间接影响：侵袭性肺炎球菌病趋势的解释
J Infect Dis. 2006 Jun 1;193(11):1487-94. doi: 10.1086/503805. Epub 2006 Apr 27.
Zotero 插件